Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Orthocell Ltd ( (AU:OCC) ) has provided an announcement.
Orthocell has reported record first-half FY26 revenue of $6.2 million, up 48% year-on-year, driven by rising adoption of its Striate+ and Remplir products and improved gross margins of 55%. The company remains loss-making, with a $5.2 million net loss after tax reflecting heavy investment in U.S. commercial infrastructure, automation and systems to support its global scale-up.
The U.S. launch of Remplir is advancing, with approvals secured in 45 states and growing hospital account penetration, while national distribution in Canada and new channels in Hong Kong bolster its international footprint. Orthocell is also targeting nerve-sparing prostate surgery and preparing EU and U.K. market entry, supported by a strong $49.4 million cash position and portfolio expansion via PearlBone, which together position the company for broader market access and long-term growth.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Ltd is a Perth-based regenerative medicine company listed on the ASX that develops and commercialises biologic and medical device products for nerve repair and related surgical procedures. Its key products include Striate+ and the higher-margin Remplir nerve repair device, with a growing international focus on the U.S., Canada, Europe, the U.K. and Asia-Pacific markets.
Average Trading Volume: 437,057
Technical Sentiment Signal: Hold
Current Market Cap: A$253.7M
For detailed information about OCC stock, go to TipRanks’ Stock Analysis page.